Recap: Integra Lifesciences Q4 Earnings
Portfolio Pulse from Benzinga Insights
Integra Lifesciences (NASDAQ:IART) reported Q4 earnings with an EPS of $0.89, missing estimates by -1.0% and a revenue decrease of $983 thousand from the previous year. Despite missing EPS estimates last quarter, the share price increased by 1.0% the following day. The company has had mixed earnings performance over the past year.
February 28, 2024 | 11:05 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Integra Lifesciences reported a slight miss in Q4 earnings with an EPS of $0.89 against estimates of $0.9 and a revenue decrease from the previous year.
The slight miss in EPS and decrease in revenue could be seen as negative, but considering the company's history of resilience post-earnings miss, the impact is likely to be neutral in the short term. The previous quarter's performance, where a miss in EPS was followed by a share price increase, suggests that investors may have already adjusted expectations.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100